Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2009 3
2010 2
2011 3
2012 7
2013 5
2014 6
2015 10
2016 11
2017 12
2018 16
2019 31
2020 28
2021 33
2022 39
2023 50
2024 57
2025 66
2026 52

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

377 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yihan li (415 results)?
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
Finerenone in Persons with Chronic Kidney Disease without Diabetes.
Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Jongs N, Smeijer JD, Brinker M, Rethemeier N, Schloemer P, Vesterinen P, Goldsbury D, Dizayee S, Mares JW, Perkovic V; FIND-CKD Investigators. Heerspink HJL, et al. N Engl J Med. 2026 Aug 6;395(6):533-545. doi: 10.1056/NEJMoa2604625. Epub 2026 Jun 4. N Engl J Med. 2026. PMID: 42246672 Clinical Trial.
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.
Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, Sarafidis PA, Tuttle KR, Wanner C, Brinker MD, Dizayee S, Kolkhof P, Schloemer P, Vesterinen P, Perkovic V; FIND-CKD investigators. Heerspink HJL, et al. Nephrol Dial Transplant. 2025 Feb 4;40(2):308-319. doi: 10.1093/ndt/gfae132. Nephrol Dial Transplant. 2025. PMID: 38858818 Free PMC article.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.
Neuen BL, Perkovic V, Agarwal R, Cherney DZI, Lam CSP, Wanner C, Tuttle KR, Sarafidis P, Barratt J, Burgner A, Chen X, Chew-Wong A, Dobronravov VA, Floege J, McCafferty K, Nangaku M, Packham D, Papachristou E, Pergola PE, Speeckaert MM, Subbiah A, Tang SCW, Tang S, Yeo SC, Jongs N, Smeijer JD, Berger M, Brinker M, Dayoub R, Elliott J, Li N, Mueller K, Rethemeier N, Finkelsztein MY, Heerspink HJL; FIND-CKD Investigators. Neuen BL, et al. JAMA. 2026 Jul 21;336(3):224-235. doi: 10.1001/jama.2026.9923. JAMA. 2026. PMID: 42246414 Free article. Clinical Trial.
Exosome-like nanovesicles derived from Phellinus linteus inhibit Mical2 expression through cross-kingdom regulation and inhibit ultraviolet-induced skin aging.
Han J, Wu T, Jin J, Li Z, Cheng W, Dai X, Yang K, Zhang H, Zhang Z, Zhang H, Fan R, Zheng S, Liu H, Li Y, Zhao H, Yao C, Lin T, Zhu C, Liu H. Han J, et al. Among authors: li y. J Nanobiotechnology. 2022 Oct 21;20(1):455. doi: 10.1186/s12951-022-01657-6. J Nanobiotechnology. 2022. PMID: 36271377 Free PMC article.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.
Merkt W, Rodon L, Deicher FS, Freitag M, Claus M, Lister R, Han H, Zhou Y, Horne A, Stütz A, Li YN, Kreuter M, Kahn N, Schneider MA, Egea-Zorrilla A, Blasco-Iturri Z, Nikulina N, Turkowski K, Ruppert C, Guenther A, Rizzo R, Rizzo S, Ferraresi M, Hübschmann D, Haas S, Blank N, Watzl C, Tykocinski LO, Lorenz HM, Savai R, Pardo-Saganta A, Lagares D. Merkt W, et al. Sci Transl Med. 2026 May 13;18(849):eadq5442. doi: 10.1126/scitranslmed.adq5442. Epub 2026 May 13. Sci Transl Med. 2026. PMID: 42127218
Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis.
Grönberg C, Rattik S, Tran-Manh C, Zhou X, Rius Rigau A, Li YN, Györfi AH, Dickel N, Kunz M, Kreuter A, Matei EA, Zhu H, Skoog P, Liberg D, Distler JH, Trinh-Minh T. Grönberg C, et al. Ann Rheum Dis. 2024 Aug 27;83(9):1156-1168. doi: 10.1136/ard-2023-225158. Ann Rheum Dis. 2024. PMID: 38594058 Free PMC article.
377 results